Who should not take FOXO4-DRI?
Documented caution flags for FOXO4-DRI include active malignancy (apoptotic effects on cells in unstable states) and pregnancy / nursing. This is not exhaustive, and absence from this list is not a safety clearance. Anyone pregnant, nursing, or managing a serious medical condition should only consider it under a doctor's care, and safety data for FOXO4-DRI is limited.
Documented caution flags for FOXO4-DRI
- Active malignancy (apoptotic effects on cells in unstable states)
- Pregnancy / nursing
- Anyone risk-averse to pre-clinical-only data
Reported side effects to weigh
- Limited human safety data
- Theoretical: off-target apoptosis in healthy tissue
- Injection-site reaction
References
- Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging — Baar MP et al., Cell, 2017
- Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline — Alameen AAM et al., Naunyn-Schmiedeberg's Arch Pharmacol, 2026
- FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation — Kong YX et al., Communications Biology, 2025
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on FOXO4-DRI
Last updated 2026-06-15.